FTO and central nervous system cancer: This subset of progressed gliomas exhibiting a loss of IDH1 heterozygosity (resulting in reduced D-2-HG generation like that seen in BT142 cells) are thus likely to show sensitivity to FTO inhibitors, similarly to IDH1wt gliomas.